Skip to main content
. 2021 Feb 15;18(1):88–104. doi: 10.20892/j.issn.2095-3941.2020.0096

Figure 1.

Figure 1

The changes in BYSL expression in glioma tissues and association of BYSL levels with patient survival. (A) Expression analysis of the GSE16011 dataset revealed a significant increase in the BYSL mRNA levels in grade II, grade III, and grade IV glioma tissues compared to those in nontumor tissues. (B, C) Expression analysis with the GEPIA showed that BYSL expression was significantly higher in low grade gliomas and in glioblastomas than those in their respective controls. T: tumor; N: normal. (D) The qRT-PCR analysis showed the upregulation of the BYSL mRNA levels in grade II, grade III, and grade IV glioma tissues compared to those in nontumor tissues. (E, F) Western blot analysis showed an increase in BYSL protein levels in grade II, grade III, and grade IV glioma tissues compared to those in nontumor tissues. (G, H) Immunohistochemistry showed that BYSL immunoreactive (BYSL-IR) signals were distributed in both the cytoplasm and nucleus of tumor cells (G). Scale bars: 100 μm for a and c; 20 μm for b and d. Quantitative analysis of the cell numbers showed increased percentages of BYSL-IR cells in grade II (n = 4), grade III (n = 4), and grade IV (n = 5) glioma tissues relative to those in nontumor tissues (n = 5) (H). (I, J) Survival analysis showed that high BYSL levels were associated with poor prognoses in both TCGA (I) and CGGA (J) glioma datasets. M, molecular marker (*P < 0.05; **P < 0.01; ***P < 0.001).